Expansion Opportunities Apyx Medical recently launched AYON, a next generation body contouring platform, signaling strategic growth and integration of their technology stack. This presents cross-sell potential to existing customers of Renuvion/J-Plasma and opens doors to clinics expanding cosmetic and surgical offerings in new markets.

International Growth The July 2025 China launch of Renuvion demonstrates an active international expansion plan. This creates outbound sales opportunities for distributors and direct sales teams to partner with regional healthcare providers, capitalizing on rising demand for minimally invasive aesthetic and surgical solutions outside the U.S.

Financial Momentum Recent quarterly revenue of $12.5 million in Q1 2026 shows solid year-over-year growth, indicating increasing adoption of Apyx Medical’s technologies. This supports proactive outreach to high-volume cosmetic surgery practices and hospital systems seeking innovative energy-based platforms.

Award-Winning Credibility Recognition such as the 2025 NewBeauty Award for Best Minimally Invasive Skin Tightener enhances brand credibility with aesthetics-focused clinics and influence channels, providing compelling proof points for expanding to new customers and renewing or upselling existing accounts.

Cosmetic-Surgical Synergy Apyx’s core products Renuvion and J-Plasma target both cosmetic and surgical markets with energy-based solutions. This dual-market positioning allows a balanced ICP focus across plastic surgeons, dermatologists, and outpatient surgical centers, enabling multi-vertical outreach and bundled solution selling.